Pomalidomide, bortezomib, and dexamethasone (PVd) in lenalidomide (LEN)-pretreated relapsed refractory multiple myeloma: Subanalysis of patients with renal impairment in OPTIMISMM.
Fredrik Schjesvold(Oslo University Hospital), Paul G. Richardson(Harvard University), Katja Weisel(Universität Hamburg), Alessandra Larocca(Cornell University), Meletios Α. Dimopoulos(Korea University), Münci Yağcı(Gazi University), Tsvetan Biyukov(Bristol-Myers Squibb (Switzerland)), Lara Grote(Bristol-Myers Squibb (United States)), Shankar Srinivasan(Rutgers, The State University of New Jersey), Filiz Vural(Ege University), Albert Oriol(Institut Català d'Oncologia), Abraham S. Kanate(HonorHealth), Larry Anderson(The University of Texas Southwestern Medical Center), Anna Marina Liberati(University of Perugia), Jindriska Lindsay(East Kent Hospitals University NHS Foundation Trust), Mónica Galli(Ospedale Papa Giovanni XXIII), Meral Beksaç(Liv Hospital), Eva Casal Mendez(Bristol-Myers Squibb (United States)), Ruiyun Jiang(Bristol-Myers Squibb (United States)), Paweł Robak(Medical University of Lodz)
Cited by 2
Related Papers
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k